Suscribirse

N-butanol extract of Broussonetia papyrifera (L.) L′Hér. ex Vent root bark alleviates atopic dermatitis by targeting E3 ubiquitin ligase WWP1 to promote NLRP3 degradation - 08/11/24

Doi : 10.1016/j.biopha.2024.117561 
Cheng Zeng b, c, 1, Liangkun Weng c, 1, Yuanming Song c, 1, Yihang Huang a, Wenjing Xiang a, Zhiming Ye c, Can Yu c, Zixuan Lai a, Yuxuan Song a, Huiwen Yang a, , Luyong Zhang c, , Bing Liu a, b,
a School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China 
b Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510699, China 
c Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China 

Correspondence to: School of Pharmacy, Guangdong Pharmaceutical University, 280 East Huan Road, Panyu District, Guangzhou City, Guangdong Province 510006, China.School of Pharmacy, Guangdong Pharmaceutical University280 East Huan Road, Panyu DistrictGuangzhou CityGuangdong Province510006China

Abstract

Background

Broussonetia papyrifera (L.) L′Hér. ex Vent (B. papyrifera) is a deciduous tree widely distributed in Asia. Previous studies have revealed that leaves of B. papyrifera ameliorated atopic dermatitis (AD)-like symptoms and inflammatory response. However, the impact and underlying mechanism of other parts of B. papyrifera on AD remain elusive.

Methods

The AD mice induced by 1-Chloro-2,4-dinitrochlorobenzene were used to observe the histopathological alterations in the skin tissues using hematoxylin-eosin staining and toluidine blue staining techniques. Serum levels of inflammatory factors were quantified utilizing ELISA. Pyroptosis was analyzed by lactate dehydrogenase release and flow cytometry in human keratinocytes. The activation of Nod-like receptor protein 3 (NLRP3) inflammasome was analyzed by western blots. Furthermore, the mechanism underlying the inhibition of NLRP3 inflammasome by N-butanol extracts of B. papyrifera root bark (NE-BPRB) was investigated using cellular thermal shift assay and surface plasmon resonance techniques.

Results

Treatment with NE-BPRB significantly ameliorated symptoms of AD mice and reduced serum levels of pro-inflammatory factors. NE-BPRB intervention exhibited inhibitory effects on NLRP3 inflammasome activation and pyroptosis in vitro and in vivo. NE-BPRB and its primary bioactive constituent chlorogenic acid (CA) promote the K48-linked ubiquitination of NLRP3, leading to its proteasomal degradation by binding WW domain containing E3 ubiquitin protein ligase 1 (WWP1).

Conclusions

The NE-BPRB and its primary bioactive constituent, CA, effectively inhibit the formation of the NLRP3 inflammasome and impede cell pyroptosis by promoting K48-linked ubiquitin-dependent proteasomal degradation of NLRP3 through binding to the E3 ubiquitin ligase WWP1, thereby resulting in improved AD.

El texto completo de este artículo está disponible en PDF.

Graphical Abstract




 : 

The CA in NE-BPRB promotes the degradation of NLRP3 by enhancing K48-linked ubiquitination through binding with the E3 ubiquitin ligase WWP1. This process disrupts the formation of the NLRP3 inflammasome and inhibits cell pyroptosis, thereby improving AD.


The CA in NE-BPRB promotes the degradation of NLRP3 by enhancing K48-linked ubiquitination through binding with the E3 ubiquitin ligase WWP1. This process disrupts the formation of the NLRP3 inflammasome and inhibits cell pyroptosis, thereby improving AD.

El texto completo de este artículo está disponible en PDF.

Highlights

NE-BPRB relieves symptoms of atopic dermatitis.
NE-BPRB inhibits activation of NLRP3 inflammasome and pyroptosis.
NE-BPRB promotes K48 link-ubiquitinated degradation of NLRP3.
NE-BPRB and its principal component CA promote NLRP3 degradation by binding to the E3 ubiquitin ligase WWP1.

El texto completo de este artículo está disponible en PDF.

Abbreviations : AD, ASC, CA, Cas-1 p20, CC50, CCK-8, CHX, DMSO, CETSA, DMEM, Dex, DNCB, DTX3L, ELISA, ECL, EE, FBS, GSDMD, GSDMD-NT, H&E, IBMDM, IgE, IFN-γ, IL, IP, QRT-PCR, LDH, MG132, MARCHF7, NE-BPRB, NLRP3, 3-MA, TCM, TNF-α, TRIM31, Ub, WWP1

Keywords : Broussonetia papyrifera (L.) L′Hér. ex Vent, Atopic dermatitis, NLRP3 inflammasome, Pyroptosis, Ubiquitination, WWP1


Esquema


© 2024  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 180

Artículo 117561- novembre 2024 Regresar al número
Artículo precedente Artículo precedente
  • Carnosic acid ameliorates postinflammatory hyperpigmentation by inhibiting inflammatory reaction and melanin deposition
  • Heyi Su, Fan Yang, Keyi Lu, Jiaxian Ma, Guangming Huo, Shengjie Li, Jianmei Li
| Artículo siguiente Artículo siguiente
  • Oleanolic acid 28-O-β-D-glucopyranoside: A novel therapeutic agent against ulcerative colitis via anti-inflammatory, barrier-preservation, and gut microbiota-modulation
  • Caixia Wang, Hanlin Liu, Zhuoqiao Li, Qingya Yang, Qianyun Wang, Ting Yang, Daohao Tang, Cuizhu Wang, Jinping Liu

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.